Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease
- PMID: 20144646
- PMCID: PMC2847049
- DOI: 10.1016/j.mad.2010.01.009
Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease
Abstract
LRRK2 mutations are recognized as the most frequent genetic cause of both familial and sporadic parkinsonism identified to date. A remarkable feature of this form of parkinsonism is the variable penetrance of symptom manifestation resulting in a wide range of age-at-onset in patients. Herein we use a functional approach to identify the Lrrk1 protein as a potential disease modifier demonstrating an interaction and heterodimer formation with Lrrk2. In addition, evaluation of LRRK1 variants in our large Lrrk2 p.G2019S-parkinsonism series from a Tunisian (n=145) identified a missense mutation (p.L416M) resulting in an average 6.2 years younger age at disease onset. In conclusion we show that the interaction of Lrrk1-Lrrk2 can form protein dimers and this interaction may influence the age of symptomatic manifestation in Lrrk2-parkinsonism patients.
2010 Elsevier Ireland Ltd. All rights reserved.
Figures




Similar articles
-
Disease penetrance of late-onset parkinsonism: a meta-analysis.JAMA Neurol. 2014 Dec;71(12):1535-9. doi: 10.1001/jamaneurol.2014.1909. JAMA Neurol. 2014. PMID: 25330418
-
DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.Lancet Neurol. 2016 Nov;15(12):1248-1256. doi: 10.1016/S1474-4422(16)30203-4. Epub 2016 Sep 28. Lancet Neurol. 2016. PMID: 27692902
-
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism.Int J Mol Sci. 2021 Jan 21;22(3):1045. doi: 10.3390/ijms22031045. Int J Mol Sci. 2021. PMID: 33494262 Free PMC article. Review.
-
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.Neurology. 2008 Apr 15;70(16 Pt 2):1456-60. doi: 10.1212/01.wnl.0000304044.22253.03. Epub 2008 Mar 12. Neurology. 2008. PMID: 18337586 Free PMC article.
-
LRRK2: Genetic mechanisms vs genetic subtypes.Handb Clin Neurol. 2023;193:133-154. doi: 10.1016/B978-0-323-85555-6.00018-7. Handb Clin Neurol. 2023. PMID: 36803807 Review.
Cited by
-
A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway.Mol Neurodegener. 2017 Jul 11;12(1):54. doi: 10.1186/s13024-017-0193-9. Mol Neurodegener. 2017. PMID: 28697798 Free PMC article.
-
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice.Proc Natl Acad Sci U S A. 2010 May 25;107(21):9879-84. doi: 10.1073/pnas.1004676107. Epub 2010 May 10. Proc Natl Acad Sci U S A. 2010. PMID: 20457918 Free PMC article.
-
Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.Elife. 2024 Jun 10;12:RP92673. doi: 10.7554/eLife.92673. Elife. 2024. PMID: 38856715 Free PMC article.
-
The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Biochem J. 2016 Feb 1;473(3):221-32. doi: 10.1042/BJ20150985. Biochem J. 2016. PMID: 26811536 Free PMC article. Review.
-
A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease.Parkinsons Dis. 2012;2012:324521. doi: 10.1155/2012/324521. Epub 2012 Dec 3. Parkinsons Dis. 2012. PMID: 23251830 Free PMC article.
References
-
- Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008;70:1456–1460. - PMC - PubMed
-
- Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a casecontrol genetic study. Lancet Neurol. 2008;7:591–594. - PubMed
-
- Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007;3:e82. - PMC - PubMed
-
- Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet. 2006;15:223–232. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases